XTRA:1SXPLife Sciences
Assessing SCHOTT Pharma KGaA (XTRA:1SXP) Valuation After Q1 2026 Earnings Beat And Reaffirmed Guidance
Why SCHOTT Pharma KGaA (XTRA:1SXP) Is Back on Investors’ Radar
SCHOTT Pharma KGaA (XTRA:1SXP) is in focus after Q1 2026 earnings showed higher sales, net income and earnings per share year over year, with management reiterating its revenue growth and margin guidance.
See our latest analysis for SCHOTT Pharma KGaA.
The recent Q1 beat and confirmed guidance came after several eventful weeks, including a €0.18 per share dividend approval and news of a CEO transition planned for May. The share...